Leading firms launch alliance to expand US biomanufacturing capacity

A group of leading US biotechnology firms has announced the formation of the American Alliance for Biomanufacturing (AAB), a new industry coalition dedicated to advancing the nation’s biomanufacturing capabilities. The initiative aims to boost domestic innovation, improve supply chain resilience, and expand the US role in the rapidly growing global bioeconomy.

Launched on May 21, the alliance brings together stakeholders from across the industrial biomanufacturing ecosystem, including CEOs and executives from companies such as Manus, Pivot Bio, Novonesis North America, Kula Bio, and LanzaTech Global. The coalition’s formation follows recent calls by the National Security Commission on Emerging Biotechnology (NSCEB) for a coordinated national strategy to reinforce U.S. leadership in the sector.

“Biomanufacturing is no longer just a scientific opportunity; it is a strategic imperative,” said Ajikumar Parayil, CEO of Manus. “The Alliance represents a step toward aligning innovation with job creation, supply chain security, and competitiveness.”

The sector encompasses a wide range of applications, including agriculture, energy, chemicals, materials, nutrition, and pharmaceuticals. Biomanufacturing uses living systems—such as cells, enzymes, or microbes—to produce goods ranging from sustainable plastics and fertilizers to food ingredients and biofuels. The global biomanufacturing market is currently valued at $20 billion and is expected to expand significantly over the next decade.

The AAB has identified two primary goals: first, to increase US demand for biobased products and technologies; and second, to ensure market readiness for both existing and emerging bioproducts. The group also aims to bolster domestic supply chains for biomanufacturing inputs and infrastructure—key components of national economic and security strategy.

Several founding members emphasized the economic and environmental potential of biomanufacturing. Chris Abbott, CEO of Pivot Bio, pointed to the development of lower-cost, high-performing agricultural products that reduce reliance on global supply chains. Leticia Gonçalves of IFF Health & Biosciences highlighted the role of biomanufacturing in building a sustainable, science-driven economy. Jennifer Holmgren of LanzaTech underscored the sector’s capacity to revitalize rural areas and create high-quality jobs.

Brooke Coleman, Executive Director of the Alliance, framed the effort in geopolitical terms. “By working together and recognizing global realities, we can ensure that the US retains its edge in scaling the biological products and processes that will define the 21st-century economy,” Coleman said.

The alliance marks a rare moment of strategic alignment across sectors traditionally focused on different applications of biotechnology. Its members include startups, multinationals, and venture-backed firms, unified by a common objective: securing America’s position in the next wave of industrial transformation.